Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RVMD Revolution Medicines, Inc.

Market Closed 12-05 16:00:00 EST

79.64

+1.16

+1.48%

盘后79.00

-0.64-0.80%

19:54 EST

High79.82	Low77.89	Vol1.71M
Open78.48	D1 Closing78.48	Amplitude2.45%
Mkt Cap15.40B	Tradable Cap13.14B	Total Shares193.32M
T/O135.63M	T/O Rate1.04%	Tradable Shares165.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":79.64,"timestamp":1764968400000,"preClose":78.48,"halted":0,"volume":1712953,"hourTrading":{"tag":"盘后","latestPrice":79,"preClose":79.64,"latestTime":"19:54 EST","volume":402661,"amount":32068123.2295,"timestamp":1764982493978},"delay":0,"floatShares":165000000,"shares":193319805,"eps":-5.193111,"marketStatus":"Market Closed","change":1.16,"latestTime":"12-05 16:00:00 EST","open":78.48,"high":79.815,"low":77.89,"amount":135632594.92321,"amplitude":0.024529,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.193111,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1581570000000,"exchange":"NASDAQ","adjPreClose":78.48,"preHourTrading":{"tag":"盘前","latestPrice":78.11,"preClose":78.48,"latestTime":"09:27 EST","volume":506,"amount":39858.76103,"timestamp":1764944830037},"postHourTrading":{"tag":"盘后","latestPrice":79,"preClose":79.64,"latestTime":"19:54 EST","volume":402661,"amount":32068123.2295,"timestamp":1764982493978},"volumeRatio":0.924533,"impliedVol":0.5433,"impliedVolPercentile":0.764},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"2589244844","title":"Deutsche Bank to Move Into Revolut’s Canary Wharf Headquarters - FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2589244844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589244844?lang=en_us&edition=fundamental","pubTime":"2025-12-06 13:03","pubTimestamp":1764997431,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251206:nFWN3XB13A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2586260282","title":"Revolution Medicines Director and Officer Mark A. Goldsmith Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260282","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260282?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:16","pubTimestamp":1764191796,"startTime":"0","endTime":"0","summary":"Mark A. Goldsmith, Director and Officer of Revolution Medicines Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL6n04yn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director and Officer Mark A. Goldsmith Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2585150115","title":"Revolution Medicines Director and Officer Mark A. Goldsmith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150115","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150115?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:24","pubTimestamp":1763673867,"startTime":"0","endTime":"0","summary":"Mark A. Goldsmith, a Director and Officer at Revolution Medicines Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL8qqZLb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director and Officer Mark A. Goldsmith Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2584189379","title":"U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe's","url":"https://stock-news.laohu8.com/highlight/detail?id=2584189379","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584189379?lang=en_us&edition=fundamental","pubTime":"2025-11-20 16:25","pubTimestamp":1763627108,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe'sNov 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agios P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nL4N3WW0LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","NVDY","ACM","MDGL","2NVD.UK","LU1868837136.USD","RVMD","NVD2.UK","TGT","NVDL","BHVN","RRC","NVDD","NVDS","ROP","NVD","NVD3.UK","NVDS.UK","NVDU","WSM","SEMR","NVDA","Q","JACK","LU1868836591.USD","AVAV","LU2279689827.SGD","PTGX","LU2756315664.SGD","LU1548497426.USD","3NVD.UK","AGIO","DY","GLOB","LOW","LU0170899867.USD","SNVD.UK","LU1169589451.USD","UNH","NVDX","KGC","ENTG","VVV","IONQ","PANW","NVIW.SI","OPK","IE0002141913.USD","AIZ","TJX"],"gpt_icon":0},{"id":"2584978904","title":"Revolution Medicines Inc : JP Morgan Raises Target Price to $92 From $82","url":"https://stock-news.laohu8.com/highlight/detail?id=2584978904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584978904?lang=en_us&edition=fundamental","pubTime":"2025-11-20 12:41","pubTimestamp":1763613694,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW04F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2584394486","title":"Jefferies Remains a Buy on Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584394486","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584394486?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:35","pubTimestamp":1763559344,"startTime":"0","endTime":"0","summary":"Jefferies analyst maintained a Buy rating on Revolution Medicines today and set a price target of $88.00. In a report released on November 6, Bank ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-revolution-medicines-rvmd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-remains-a-buy-on-revolution-medicines-rvmd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2584954950","title":"Revolution Medicines Initiated at Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2584954950","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584954950?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:54","pubTimestamp":1763484840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 18, 2025 11:54 ET (16:54 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"gpt_icon":0},{"id":"2583635189","title":"Revolution Medicines Director and Officer Mark A. Goldsmith Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583635189","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583635189?lang=en_us&edition=fundamental","pubTime":"2025-11-15 09:46","pubTimestamp":1763171186,"startTime":"0","endTime":"0","summary":"Mark A. Goldsmith, Director and Officer of Revolution Medicines Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251115:nNDLbxPbYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director and Officer Mark A. Goldsmith Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2583512696","title":"Revolution Medicines CFO Jack Anders Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583512696","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583512696?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:21","pubTimestamp":1763068886,"startTime":"0","endTime":"0","summary":"Jack Anders, Chief Financial Officer of Revolution Medicines Inc., reported a disposal of common shares of Revolution Medicines Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL2CBMRk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Revolution Medicines CFO Jack Anders Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2582664568","title":"How Daraxonrasib’s FDA Breakthrough and Orphan Designations Have Changed Revolution Medicines’ (RVMD) Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2582664568","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582664568?lang=en_us&edition=fundamental","pubTime":"2025-11-09 00:37","pubTimestamp":1762619849,"startTime":"0","endTime":"0","summary":"Earlier this week, Revolution Medicines announced that its lead candidate daraxonrasib received both FDA Breakthrough Therapy and Orphan Drug designations, following reports of a 47% objective response rate in first-line metastatic pancreatic cancer and confirmation of progressing Phase III trials.\nThese regulatory milestones, coupled with promising clinical data, have drawn substantial attention to the company’s expanding precision oncology pipeline aimed at difficult-to-treat...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/how-daraxonrasibs-fda-breakthrough-and-orphan-designations-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rvmd/revolution-medicines/news/how-daraxonrasibs-fda-breakthrough-and-orphan-designations-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2581025697","title":"RBC Capital Keeps Their Buy Rating on Revolution Medicines (RVMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581025697","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581025697?lang=en_us&edition=fundamental","pubTime":"2025-11-07 09:49","pubTimestamp":1762480143,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Revolution Medicines, with a price target of $77.00. Ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-revolution-medicines-rvmd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":"46fe14036bd3cdaf869148f08f7adcff","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-revolution-medicines-rvmd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD"],"gpt_icon":0},{"id":"2581099718","title":"Revolution Medicines Inc : Bofa Global Research Raises Price Objective to $82 From $80","url":"https://stock-news.laohu8.com/highlight/detail?id=2581099718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581099718?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:06","pubTimestamp":1762438011,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI2MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2581709610","title":"Revolution Medicines Inc : Needham Raises Target Price to $72 From $66","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709610?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:41","pubTimestamp":1762436487,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI2H7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2581093401","title":"Revolution Medicines Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2581093401","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581093401?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:04","pubTimestamp":1762434240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RVMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2025 08:04 ET (13:04 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"gpt_icon":0},{"id":"1159057358","title":"Stock Track | Revolution Medicines Soars 7.48% Pre-market on Multiple Analyst Upgrades","url":"https://stock-news.laohu8.com/highlight/detail?id=1159057358","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159057358?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:10","pubTimestamp":1762431059,"startTime":"0","endTime":"0","summary":"Shares of Revolution Medicines, Inc. (RVMD) surged 7.48% in pre-market trading on Thursday, as multiple analysts raised their price targets for the biopharmaceutical company, signaling growing...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RVMD"],"gpt_icon":0},{"id":"2581062867","title":"JPMorgan ups Revolution Medicines target, adds to Analyst Focus List","url":"https://stock-news.laohu8.com/highlight/detail?id=2581062867","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581062867?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:55","pubTimestamp":1762430155,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Brian Cheng raised the firm’s price target on Revolution Medicines (RVMD) to $82 from $71 and keeps an Overweight rating on the sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jpmorgan-ups-revolution-medicines-target-adds-to-analyst-focus-list-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jpmorgan-ups-revolution-medicines-target-adds-to-analyst-focus-list-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2505996681.GBP","IE00B1XK9C88.USD","LU0820561818.USD","LU0868494708.USD","IE00BDCRKT87.USD","LU1988902786.USD","BK4550","IE00B1BXHZ80.USD","LU1280957306.USD","LU2236285917.USD","LU0267386448.USD","LU0211331839.USD","LU0640476718.USD","LU0256863811.USD","IE0034235295.USD","LU0320765646.SGD","LU2237443465.HKD","LU0215105999.USD","LU1145028129.USD","LU1496350171.SGD","LU1551013342.USD","LU0048584097.USD","IE00BKDWB100.SGD","BK4585","LU1116320901.HKD","LU2456880835.USD","LU0689472784.USD","LU2592432038.USD","BK4588","LU0942090050.USD","LU2023250843.SGD","LU1064131342.USD","IE00BJTD4V19.USD","IE0034235188.USD","LU2505996509.AUD","LU2552382058.USD","IE00BJTD4N35.SGD","LU0203347892.USD","LU2054465674.USD","LU2552382215.SGD","LU0203345920.USD","LU1162221912.USD","IE00B3S45H60.SGD","RVMD","LU1261432733.SGD","IE00BJLML261.HKD","LU1894683264.USD","LU1496350502.SGD","LU1914381329.SGD","LU1032466523.USD"],"gpt_icon":0},{"id":"2581748061","title":"Wedbush Lifts Price Target on Revolution Medicines to $80 From $77, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581748061","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581748061?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:47","pubTimestamp":1762429625,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) has an average rating of buy and mean price target of $79.45, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD"],"gpt_icon":0},{"id":"2581202039","title":"Revolution Medicines Inc : Leerink Partners Raises Target Price to $74 From $67","url":"https://stock-news.laohu8.com/highlight/detail?id=2581202039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581202039?lang=en_us&edition=fundamental","pubTime":"2025-11-06 12:49","pubTimestamp":1762404594,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI02U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2581038367","title":"Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2581038367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581038367?lang=en_us&edition=fundamental","pubTime":"2025-11-06 10:15","pubTimestamp":1762395332,"startTime":"0","endTime":"0","summary":"Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Revolution Medicines, boosting the price target to $104.00. Charles Zhu has given...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/revolution-medicines-promising-growth-trajectory-with-strong-financial-health-and-strategic-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/revolution-medicines-promising-growth-trajectory-with-strong-financial-health-and-strategic-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2581884707","title":"Revolution Medicines Unveils Pipeline Advancements Targeting RAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2581884707","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581884707?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:32","pubTimestamp":1762378338,"startTime":"0","endTime":"0","summary":"Revolution Medicines Inc. has released a corporate presentation outlining progress in its pipeline of targeted therapies for RAS-addicted cancers. The company is advancing three clinical-stage RAS inhibitors: daraxonrasib , elironrasib , and zoldonrasib . Daraxonrasib is being evaluated in monotherapy and combination studies for pancreatic ductal adenocarcinoma  and non-small cell lung cancer , with phase 3 trials planned for earlier treatment lines. Early clinical data for daraxonrasib in second-line PDAC show a median progression-free survival of 8.5 months and a median overall survival of 13.1 months. The company is also advancing a G12V-selective inhibitor  toward clinical readiness and expanding its global commercialization capabilities. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3f60vf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RVMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com","stockEarnings":[{"period":"1week","weight":0.0242},{"period":"1month","weight":0.3421},{"period":"3month","weight":0.9664},{"period":"6month","weight":0.9382},{"period":"1year","weight":0.6837},{"period":"ytd","weight":0.8208}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.001701},{"month":2,"riseRate":0.6,"avgChangeRate":-0.005035},{"month":3,"riseRate":0.5,"avgChangeRate":-0.029333},{"month":4,"riseRate":0.666667,"avgChangeRate":0.052764},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.03349},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042659},{"month":7,"riseRate":0.5,"avgChangeRate":-0.000709},{"month":8,"riseRate":0.666667,"avgChangeRate":0.059948},{"month":9,"riseRate":0.5,"avgChangeRate":0.038151},{"month":10,"riseRate":0.666667,"avgChangeRate":0.019949},{"month":11,"riseRate":0.833333,"avgChangeRate":0.188424},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027214}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Revolution Medicines, Inc.(RVMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}